drugset / Trial / NCT00065637
Once Weekly Parathyroid Hormone for Osteoporosis
Phase 3
Completed
50 enrolled
University of California, San Francisco
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collab
RandomizedFactorialDouble-blindTreatment
Summary
Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis. This study will evaluate the safety and effectiveness of PTH when given once a week.
Timeline
- Start
- 2003-12
- Primary completion
- 2005-09
- Completion
- 2005-09
Publications
- Background Brown SA, Rosen CJ. Osteoporosis. Med Clin North Am. 2003 Sep;87(5):1039-63. doi: 10.1016/s0025-7125(03)00065-8.
- Background Rosen CJ. The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr. 2003;13(1):25-38. doi: 10.1615/critreveukaryotgeneexpr.v13.i1.30.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teriparatide | Protein / enzyme biologic | — | — |